- $494.06m
- $491.34m
- $311.71m
Annual cashflow statement for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.2 | -29.7 | -46.3 | -17.9 | 163 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.16 | 4.19 | 5.63 | 6.41 | 16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.84 | 1.07 | 2.23 | -39.4 | 7.27 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -21.2 | -24.4 | -38.4 | -50.6 | 175 |
| Capital Expenditures | -1.43 | -0.219 | -0.327 | -0.116 | -2.26 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -7.71 | -3.49 | -16.7 | 21.3 | -306 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.13 | -3.71 | -17.1 | 21.2 | -308 |
| Financing Cash Flow Items | — | — | -0.198 | -0.29 | -2.18 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 41.8 | 17.9 | 55.9 | 26.3 | 238 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | -10.2 | 0.448 | -3.07 | 105 |